GlassScriptPhysician profile
David K Charles
NPI 1588169015
$5,167.49
in general payments reported to CMS, 2019-2025
9 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.02 · 2023: $617 · 2024: $4,346 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,945 · Food and Beverage: $976 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,945.47 |
| Food and Beverage | $976.00 |
| Education | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $2,078.85 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $1,911.08 | 2022-2024 | Ams 800 Artificial Urinary Sphincter |
| Coloplast Corp | $998.26 | 2023-2024 | Titan |
| Astellas Pharma US INC | $50.15 | 2023 | Veozah |
| Janssen Biotech, INC. | $37.63 | 2025 | |
| Endo USA, INC. | $35.97 | 2025 | Xiaflex |
| Becton, Dickinson and Company | $24.00 | 2025 | Purewick Female External Catheter |
| Merck Sharp & Dohme LLC | $16.08 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Antares Pharma, INC. | $15.47 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.